Proscia is now part of @Agilent Technologies. Today, we begin the next chapter in our mission to rewire pathology for precision medicine. Agilent shares our commitment to our customers, partners, and team, along with our vision for open, digital, and AI-enabled pathology. Together, we are well positioned to accelerate innovation for more labs and life sciences organizations and bring the benefits to the patients they serve. Thank you for being part of our journey. Here’s to all that lies ahead. Read the full announcement here: agilent.com/about/newsroom/p…

Labs now expect their digital pathology platform to give them access to AI applications from many vendors. Access is only the starting point. The platform also determines how pathologists, scientists, and lab teams use those applications day to day, and how much value they get from them. Jeni Gruensfelder, our Director of Partner Ecosystems, lays out 7 criteria for evaluating how a digital pathology platform supports AI. Each one comes with practical questions labs and life sciences organizations can ask vendors. Read the full post: proscia.com/blog/choosing-th…

Pumpkins carved, costumes judged, and our logo lit up in a jack-o’-lantern. Happy Halloween from the Proscia team!

Join us November 18 for a candid, customer-led discussion with lab leaders from PathGroup and P&C Labs who are already running AI on Concentriq. Hear firsthand how they built the business case, selected use cases, and scaled AI across their teams and sites. Whether you’re evaluating AI for the first time or preparing to expand what you’ve already deployed, gain practical guidance from peers who are putting AI into practice. Register now: info.proscia.com/image-analy…

Concentriq is mission-critical for pathology labs and drug developers. When a problem comes up, every minute counts. Standard monitoring tools can tell you a request was slow. We needed to know which step in processing a specific slide slowed down and for which customer. So our engineering team built a new observability system on AWS, which shows engineers what’s happening inside Concentriq, not only that something is slow. It collects telemetry, the performance data Concentriq produces as it runs, and keeps that history indefinitely. When a problem shows up in that data, engineers now trace the cause in a median of 10 minutes. The system is built to meet Concentriq’s compliance obligations, including privacy rules like HIPAA and GDPR. Customers benefit too. Labs can see how their teams use Concentriq, and IT teams can feed this data into their own monitoring tools. AWS featured the work by our Vice President of Technology Operations, Jeff Rhude, and our Senior Reliability Engineer, Kyriakos Toulgaridis, on its Storage Blog. aws.amazon.com/blogs/storage…

We’ll be collaborating with Columbia University to identify biomarkers for neurodegenerative diseases such as Alzheimer’s and other dementias. Columbia is world-renowned for its pathology leadership, research, and patient care. Combined with our pathology AI expertise, we aim to drive new discoveries that link biomarker and therapeutic development. Read the full announcement: proscia.com/press-release/pr…

When SpecialtyVETPATH’s ocular pathologist needed to relocate to Massachusetts for family reasons, remote collaboration went from a nice-to-have to a mission-critical priority. There was just one catch: Dr. Jennifer Ward, DVM, CEO and Co-Laboratory Director, had no IT background and no in-house IT team to help her with the transition. Instead of backing down, Dr. Ward took on the learning curve herself. She tapped into her network across academia and human pathology and led her lab through the complexities of going digital. Hear more stories in our Feats of Strength series: info.proscia.com/feats-of-st…

“Epic-native” is often used loosely, but for health systems and academic medical centers running Epic Beaker, the distinction matters. Swipe through to see what “Epic-native” digital pathology really means, and read the full breakdown from our Senior Integration Manager, Jacob Blaylock, here: proscia.com/blog/maximizing-…

For over a decade, our mission has been to rewire pathology for precision medicine. Since we shared our vision, change across diagnostic laboratories and life sciences organizations has only sped up. There’s still a lot of work ahead to make precision medicine the standard, but the beliefs behind that future remain the same. Revisit our full vision here: proscia.com/blog/rewiring-pa…

ICYMI: Last week at SREcon EMEA 2026 in Dublin, Kyriakos Toulgaridis and Jeff Rhude shared how we changed our observability story with ClickHouse, OpenTelemetry, and a different approach to the problem. A big thank you to everyone who attended the talk!

Concentriq serves more than 4,000 laboratories, hospitals, and clinics, and has powered 30,000+ studies from discovery to trials. Stop by booth 306 to see our platform and meet the team behind it. At 2:30 PM, users from Cleveland Clinic will join us to share their experience.

See you tonight, #PathVisions26!

Our CEO @davidwest_irl shared his thoughts on our recent news. Read more below. linkedin.com/pulse/next-chap…

Proscia has entered into a definitive agreement to be acquired by @Agilent. For over a decade, our mission has been to rewire pathology for precision medicine. Joining Agilent brings the scale and resources to deliver on that mission faster, for the same customers and team that got us here. Read more here: proscia.com/press-release/ag…

Kary Rogers spent more than 15 years leading enterprise support at networking and security companies, where a product failure means nobody works. That is where he learned what mission-critical means. At Proscia, the stakes carry a different weight. Our customers’ work informs a diagnosis with real impact on patients and their loved ones, shaping how we build and support our product. Hear from Kary, our Vice President of Global Support, in the clip below and read the full conversation: proscia.com/blog/getting-to-…

Companion diagnostic programs rarely follow a fixed path. Biomarkers evolve, new algorithms emerge, and the partners or technologies needed later in development may look very different from those needed at the start. The architecture supporting those programs should leave room for that evolution. At Biomarkers, CDx & Precision Medicine Europe, Labcorp's Dr. Paul Mesange will share how an open approach with our Concentriq platform can support biomarker discovery and CDx development from early exploratory work through late-phase bridging studies, without requiring sponsors to commit to a closed technology ecosystem before a program's viability is known. Join his session on October 13 at 15:20 in Conference Room 9, then visit the Proscia team at Stand 69.